How to Fight Insurance Denials for Migraine CGRP Inhibitors and Preventive Treatments

Migraine is the second-leading cause of disability worldwide, yet insurance denials for effective preventive treatments remain routine. This guide covers drugs targeting the CGRP pathway — including injectable monoclonal antibodies (Aimovig, Ajovy, Emgality, Vyepti), oral gepants (Qulipta, Nurtec, Ubrelvy, Zavzpret), and Botox for chronic migraine. Denials are common because these medications are expensive (often $700+ per month), and insurers rely on outdated step-therapy policies written before the American Headache Society's 2024 position statement, which now positions CGRP-targeting therapies as potential first-line options. This guide explains which denial templates you'll encounter, which clinical citations carry weight, and how to build a successful appeal.

Why Insurers Deny Migraine Preventives

Most denials cite one of the following templates:

1. Step therapy not completed.

The insurer requires you to fail two, three, or even four older oral preventives first — typically topiramate, propranolol, amitriptyline, valproate, or venlafaxine. Policies often cite the 2012 AAN/AHS guideline on episodic migraine prevention, which identified these drugs as "Level A" or "Level B" evidence, but ignore the 2024 AHS update allowing CGRP therapies as first-line options in appropriate patients.

2. Not medically necessary.

A vague denial asserting the drug is "investigational," "experimental," or "not appropriate" without specific justification. This often appears when your headache day count, disability score, or prior-failure documentation is missing from the initial authorization request.

3. Inadequate trial duration or dosing.

The insurer claims you didn't give an older preventive a fair chance — for example, eight weeks of propranolol when the policy requires twelve, or 50 mg of topiramate when "adequate trial" means titration to at least 100 mg daily. Some policies cite the AHS 2018 consensus requirement that oral preventives be tried at "adequate dose for at least six weeks."

4. Diagnosis doesn't meet chronic migraine criteria.

Botox is FDA-approved only for chronic migraine (≥15 headache days per month with ≥8 migraine days, lasting >3 months per ICHD-3 criteria). If your neurologist's note says "frequent migraines" without documenting day counts from a headache diary, the claim will be denied.

5. Combination therapy not covered.

Some patients respond best to Botox plus a CGRP monoclonal antibody, or Nurtec for prevention plus Ubrelvy for acute rescue. Insurers often deny the second agent as "duplicative," even though real-world data supports additive benefit and the mechanisms differ.

The Citations Insurers Respect

When you appeal, reference these guidelines and trials by name. Do not paraphrase or say "studies show" — name the study, journal, and year.

Guidelines and consensus statements:

• AHS 2024 Position Statement — "Integrating New Treatments for Acute and Preventive Treatment of Migraine into Clinical Practice" (published in Headache, 2024). This is your most powerful citation. It explicitly states that CGRP-targeting therapies may be considered first-line preventive options and do not require prior failure of older oral preventives if the patient has contraindications, intolerance risk, or preference after informed discussion.

• AHS 2018 Consensus Statement on CGRP Therapies (updated 2021) — Established that CGRP monoclonal antibodies are appropriate when a patient has ≥4 monthly migraine days with disability and meets any of the following: (a) inability to tolerate ≥2 oral preventives at adequate trial, (b) contraindication to oral preventives, or (c) inadequate response after six weeks at adequate dose for ≥2 preventives.

• ICHD-3 (International Classification of Headache Disorders, 3rd edition) — The diagnostic bible. Chronic migraine = headache ≥15 days/month for >3 months, with ≥8 days meeting migraine criteria. Medication overuse headache (MOH) = headache ≥15 days/month with regular acute medication overuse for >3 months.

• AAN/AHS Guideline on Migraine Prevention in Episodic Migraine in Adults (2012, reaffirmed) — Level A evidence for topiramate, propranolol, metoprolol, timolol, and divalproex/valproate. Level B for amitriptyline and venlafaxine. Insurers cite this frequently, but it predates all CGRP therapies.

Pivotal trials for CGRP monoclonal antibodies:

• STRIVE (Goadsby, NEJM 2017) and ARISE (Dodick, Cephalalgia 2018) — Aimovig (erenumab), FDA-approved May 17, 2018 (first-in-class).
• HALO-EM and HALO-CM (Silberstein, NEJM 2017; Dodick, JAMA 2018) — Ajovy (fremanezumab), FDA-approved September 14, 2018.
• EVOLVE-1, EVOLVE-2, and REGAIN (Stauffer and Skljarevski, JAMA Neurology 2018) — Emgality (galcanezumab), FDA-approved September 27, 2018.
• PROMISE-1 and PROMISE-2 (Ashina, Cephalalgia 2020; Lipton, Neurology 2020) — Vyepti (eptinezumab) IV infusion, FDA-approved February 21, 2020.

Pivotal trials for oral gepants:

• ADVANCE (Ailani, NEJM 2021) — atogepant (Qulipta) for episodic migraine prevention; PROGRESS (2023) for chronic migraine. FDA-approved September 28, 2021 (episodic), April 2023 (chronic).
• ACHIEVE-1 and ACHIEVE-2 (Dodick, NEJM 2019; Lipton, JAMA 2019) — ubrogepant (Ubrelvy) for acute treatment, FDA-approved December 23, 2019.
• Study 303 (Croop, Lancet 2021) — rimegepant (Nurtec ODT) for prevention. FDA expanded approval to preventive use May 27, 2021 (first dual acute/preventive oral CGRP drug).
• Zavegepant nasal pivotal (Lipton, Lancet Neurology 2023) — Zavzpret intranasal spray, FDA-approved March 9, 2023.

Botox:

• PREEMPT 1 and PREEMPT 2 (Aurora, 2010; Diener, 2010) — Phase III trials leading to FDA approval October 15, 2010 for chronic migraine. The PREEMPT protocol uses 31 fixed injection sites, 155 units baseline, up to 195 units with follow-the-pain dosing, administered every 12 weeks.

Combination therapy:

• Blumenfeld et al. real-world retrospective studies (multiple publications 2018–2021) showing additive benefit of Botox plus CGRP monoclonal antibody in refractory chronic migraine.

How to Argue Against Step Therapy Not Completed

What the denial says: "Patient must try and fail topiramate, propranolol, and amitriptyline before Aimovig will be covered."

Your counter-argument:

1. Cite the AHS 2024 Position Statement explicitly: "The American Headache Society's 2024 position statement on integrating new migraine treatments states that CGRP-targeting therapies may be considered first-line preventive options without requiring prior failure of older oral agents. This supersedes earlier step-therapy frameworks and reflects the current standard of care."

2. Document contraindications or intolerance to the required drugs. If you have asthma, propranolol and other beta-blockers are contraindicated (they can trigger bronchospasm). If you have cognitive concerns, topiramate causes "brain fog" and word-finding difficulty in a large minority of patients. If you have depression or are on SSRIs, tricyclic antidepressants like amitriptyline may worsen mood or cause dangerous serotonin interactions. If you are pregnant or planning pregnancy, valproate is teratogenic (Category X).

3. Provide evidence of actual prior trials if you did try them. For each drug, specify: drug name, maximum dose reached, duration (at least 6–8 weeks at therapeutic dose counts as adequate trial per AHS 2018), and reason for discontinuation. Example: "Topiramate 100 mg daily for 12 weeks — discontinued due to cognitive adverse effects (difficulty concentrating, word-finding problems). Propranolol 80 mg twice daily for 8 weeks — discontinued due to exacerbation of asthma symptoms."

4. Include disability scores. Submit your MIDAS (Migraine Disability Assessment Scale) or HIT-6 (Headache Impact Test) score. MIDAS ≥21 or HIT-6 ≥60 indicates severe disability. This demonstrates that the functional impact justifies a more effective, better-tolerated therapy.

5. Request an expedited appeal if the delay is causing harm. If you are missing work, school, or experiencing frequent ER visits, state this clearly and ask for an expedited review (typically 72 hours instead of 30 days).

How to Argue Against "Not Medically Necessary"

What the denial says: "Qulipta is not medically necessary for this patient."

Your counter-argument:

1. Submit objective documentation of monthly migraine days. Use a headache diary or app log showing ≥4 migraine days per month (episodic) or ≥15 headache days with ≥8 migraine days (chronic per ICHD-3). Insurers will not accept vague language like "frequent headaches."

2. Include the MIDAS or HIT-6 score to quantify disability.

3. Cite the drug's pivotal trial by name. Example: "Atogepant's efficacy was demonstrated in the ADVANCE trial (Ailani, NEJM 2021), which showed a mean reduction of 3.9 migraine days per month in the 60 mg daily arm with a favorable safety profile. The FDA approved Qulipta based on these data in September 2021."

4. Explain why this drug is appropriate for your specific situation. Oral gepants do not cause cognitive side effects, weight gain, or cardiovascular concerns, making them suitable for patients who cannot tolerate topiramate, tricyclics, or beta-blockers. If you failed or cannot take injectables, oral preventive options are limited, and Qulipta is now a first-line choice per AHS 2024.

5. Attach the prescribing neurologist's letter of medical necessity. It should reference AHS 2024, your prior treatment history, your ICHD-3 diagnosis, and the specific contraindications or failures that make this drug the appropriate choice.

How to Argue Against Inadequate Trial Duration or Dosing

What the denial says: "Patient did not complete an adequate trial of topiramate — only 50 mg for 6 weeks."

Your counter-argument:

1. Acknowledge the insurer's standard but explain why it could not be met. Example: "I attempted to titrate topiramate to 100 mg daily as recommended, but at 50 mg I experienced severe cognitive side effects (confusion, difficulty with word recall) that made it unsafe to continue my job as [teacher/nurse/driver]. Per the AHS 2018 consensus, inability to tolerate an oral preventive at adequate dose qualifies the patient for CGRP therapy."

2. Provide documentation from your physician. The neurologist should confirm the adverse event and explain why further titration was not medically advisable.

3. Cite pharmacology if relevant. Topiramate's cognitive effects are dose-related; if intolerable at 50 mg, escalation to 100 mg would worsen them. Propranolol requires careful titration in asthma or COPD patients and may still be unsafe even at low doses.

4. Show you have tried multiple drug classes. Even if one trial was suboptimal, if you also tried a beta-blocker, an antidepressant, and an anticonvulsant, you have demonstrated good-faith effort across multiple mechanisms.

How to Argue for Botox in Chronic Migraine

What the denial says: "Botox not covered — patient does not meet criteria for chronic migraine."

Your counter-argument:

1. Submit a headache diary covering at least three months showing ≥15 headache days per month, with ≥8 days meeting ICHD-3 migraine criteria (unilateral, pulsating, moderate-to-severe intensity, aggravated by activity, plus nausea/vomiting or photophobia and phonophobia).

2. Cite ICHD-3 and PREEMPT. "The International Classification of Headache Disorders, 3rd edition (ICHD-3) defines chronic migraine as headache on ≥15 days per month for >3 months, with ≥8 days meeting migraine criteria. The PREEMPT trials (Aurora 2010, Diener 2010) established onabotulinumtoxinA as effective for chronic migraine, leading to FDA approval on October 15, 2010."

3. Document prior preventive failures. Botox is typically subject to step therapy requiring ≥2 oral preventive failures. List each drug, dose, duration, and outcome.

4. Request the PREEMPT protocol. If the insurer approves only a lower dose or fewer injection sites, cite the PREEMPT protocol: 31 fixed sites, 155 units baseline, up to 195 units with follow-the-pain, every 12 weeks. Deviations from this protocol reduce efficacy.

How to Argue for Combination Therapy

What the denial says: "Emgality denied — patient already receiving Botox."

Your counter-argument:

1. Cite real-world evidence. "Blumenfeld and colleagues published multiple real-world studies (2018–2021) demonstrating that combination therapy with Botox and a CGRP monoclonal antibody produces additive benefit in patients with refractory chronic migraine. The mechanisms are complementary: Botox inhibits peripheral neurotransmitter release, while CGRP antibodies block central and peripheral CGRP signaling."

2. Document inadequate response to monotherapy. Provide headache diary data showing that Botox alone reduced your monthly migraine days from, say, 20 to 14 — meaningful but still disabling. "My MIDAS score on Botox monotherapy remains 24 (Grade IV, severe disability), justifying the addition of Emgality."

3. Explain the lack of contraindication. CGRP monoclonal antibodies and Botox have distinct mechanisms and side-effect profiles. There is no pharmacologic interaction or safety signal precluding combination use.

4. Cite AHS 2024. "The AHS 2024 position statement encourages individualized treatment plans incorporating multiple migraine-specific therapies as needed to achieve optimal outcomes."

How to Argue for Nurtec or Qulipta When You're Already on Acute Medications

What the denial says: "Nurtec ODT denied as preventive — patient already prescribed sumatriptan."

Your counter-argument:

1. Distinguish preventive from acute treatment. "Nurtec ODT (rimegepant) has a dual indication for both acute treatment and prevention of episodic migraine (FDA preventive approval May 27, 2021). I am requesting it as a preventive agent, taken every other day, which is distinct from my acute triptan use. Preventive therapy reduces the frequency of attacks, thereby decreasing my need for acute medications and reducing the risk of medication overuse headache."

2. Cite Study 303. "The preventive indication was established in Study 303 (Croop, Lancet 2021), showing a mean reduction of 4.3 migraine days per month with rimegepant 75 mg every other day."

3. Document high migraine frequency. If you have ≥8 migraine days per month, you likely meet criteria for preventive therapy. Submit your headache diary and MIDAS score.

4. Explain triptan limitations. If you have cardiovascular contraindications, aura, or hemiplegic migraine, triptans may be contraindicated or less effective. Gepants do not cause vasoconstriction and are safe in these populations.

What We Do

We help patients draft physician-ready appeal letters that cite the right guidelines, trials, and policy language. Our tools walk you through documenting monthly migraine days, prior preventive failures, contraindications, and disability scores, then generate a structured letter your neurologist can review, sign, and submit. We don't replace your doctor, but we ensure your appeal references the AHS 2024 position statement, the ADVANCE and STRIVE trials, ICHD-3 criteria, and the other authoritative sources insurers respect. Most internal appeals succeed when the clinical documentation and citations are complete.

---

Sources

1. American Headache Society. "Integrating New Treatments for Acute and Preventive Treatment of Migraine into Clinical Practice." Headache, 2024.

2. American Headache Society. "Consensus Statement: Update on Integrating New Migraine Treatments Into Clinical Practice." Headache, 2018 (updated 2021).

3. Headache Classification Committee of the International Headache Society. "The International Classification of Headache Disorders, 3rd edition (ICHD-3)." Cephalalgia, 2018.

4. American Academy of Neurology / American Headache Society. "Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults." Neurology, 2012 (reaffirmed).

5. Goadsby PJ, et al. "A Controlled Trial of Erenumab for Episodic Migraine (STRIVE)." New England Journal of Medicine, 2017.

6. Silberstein SD, et al. "Fremanezumab for the Preventive Treatment of Chronic Migraine (HALO-CM)." New England Journal of Medicine, 2017.

7. Stauffer VL, et al. "Evaluation of Galcanezumab for the Prevention of Episodic Migraine (EVOLVE-1)." JAMA Neurology, 2018.

8. Lipton RB, et al. "Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine (PROMISE-2)." Neurology, 2020.

9. Ailani J, et al. "Atogepant for the Preventive Treatment of Migraine (ADVANCE)." New England Journal of Medicine, 2021.

10. Croop R, et al. "Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial (Study 303)." Lancet, 2021.

11. Dodick DW, et al. "Ubrogepant for the Treatment of Migraine (ACHIEVE-1 and ACHIEVE-2)." New England Journal of Medicine / JAMA, 2019.

12. Lipton RB, et al. "Zavegepant intranasal for the acute treatment of migraine." Lancet Neurology, 2023.

13. Aurora SK, et al. "OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program." Headache, 2010.

14. Diener HC, et al. "OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial." Cephalalgia, 2010.

15. Blumenfeld AM, et al. "Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review." Pain and Therapy, 2021.